FAQ's
SPRAVATO® (esketamine) is an FDA-approved nasal spray used in adults with treatment-resistant depression or major depressive disorder with suicidal thoughts or actions.
No. SPRAVATO® is not experimental. It is an FDA-approved treatment offered in certified clinics like American Behavioral Clinics.
SPRAVATO® targets the brain’s glutamate system, which is different from how most antidepressants work. This may help restore connections in the brain that affect mood and thought patterns.
It may be an option for adults who have tried at least two different antidepressants without success, or for adults experiencing major depression with suicidal thoughts. A provider must evaluate you to confirm eligibility.
SPRAVATO® contains esketamine, which is chemically related to ketamine but specifically developed, tested, and FDA-approved for depression treatment.
SPRAVATO® is a nasal spray that you self-administer in the clinic under direct supervision. You then stay for at least two hours of monitoring to ensure your safety.
Treatment frequency varies. Typically, it starts twice a week for the first month, then may reduce to once a week or every other week depending on your progress.
No. Because SPRAVATO® may cause drowsiness, dissociation, or dizziness, you cannot drive until the next day after a treatment. Please arrange a ride home.
Some patients may experience dizziness, nausea, sedation, or temporary changes in perception. Your provider will review all possible risks before you begin treatment.
Many insurance plans, including Medicare and some Medicaid programs, may cover SPRAVATO®. Our team can help verify your benefits and discuss financial assistance options.
Some patients notice improvement within the first treatment, while others take longer. Results vary, and ongoing treatment is often needed to maintain progress.
